A+ A-

News & Events

Affiliated with the University of MelbourneUniversity of Melbourne Logo

INSIGHT Research #3: Prof Guymer talks to A/Prof Lyndell Lim about uveitis

In this fascinating episode, Professor Robyn Guymer talks to Associate Professor Lyndell Lim, Head, Clinical Trials Research. A/Prof Lyndell Lim, a uveitis and medical retina subspecialist, leads the Clinical Trials Research at CERA. After completing her ophthalmology training in Melbourne, A/Prof Lim then completed two Fellowships – one in medical retina at the Royal Victorian Eye and Ear Hospital, and one in uveitis/ocular inflammatory disease at the Casey Eye Institute, Portland, Oregon, USA.

A/Prof Lim’s main research interests are clinical studies in the field of uveitis and ocular immunology, and diabetic retinopathy. Her team runs both investigator initiated and sponsored clinical trials that aim to investigate new treatments in a variety of ophthalmic disease.

“Uveitis is inflammation inside the eye and my research covers infectious and non-infectious causes,” she says.

“The most pressing problem we have is how to treat uveitis, we have treatments but they all have a lot of side effects both to the eye and to the (whole) person, so what we need to do is find better and more targeted treatments,” says A/Prof Lim.

“The mainstay of treatment is steroids, but if you use too much for too long they can have blinding side-effects including cataract and glaucoma, so what we need is to try to find better formulations of drugs and better ways of delivering them to the eye,” she says.

CERA has joined international collaborative groups to tackle the scourge of uveitis through clinical trials. One of the largest is the Multicentre Uveitis Steroid Treatment (MUST) Research Group. CERA is one of only several sites chosen for to be part of this group and be involved in their research trials outside of the USA and is the only site in Australia.

A/Prof also talks about the possible links her team is investigating between uveitis, gut health and Multiple Sclerosis.